WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H122680
CAS#: N/A
Description: CDD-1281 is a potent and BMPR2-selective kinase inhibitor with IC50= 1.2nM.
Hodoodo Cat#: H122680
Name: CDD-1281
CAS#: N/A
Chemical Formula: C30H27N5O2
Exact Mass: 489.22
Molecular Weight: 489.580
Elemental Analysis: C, 73.60; H, 5.56; N, 14.31; O, 6.54
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: CDD-1281; CDD1281; CDD 1281
IUPAC/Chemical Name: N-(3-carbamoylbenzyl)-1-cyclopentyl-2-(isoquinolin-6-yl)-1H-benzo[d]imidazole-6-carboxamide
InChi Key: KDAVHUIMGSUDCW-UHFFFAOYSA-N
InChi Code: InChI=1S/C30H27N5O2/c31-28(36)21-5-3-4-19(14-21)17-33-30(37)23-10-11-26-27(16-23)35(25-6-1-2-7-25)29(34-26)22-8-9-24-18-32-13-12-20(24)15-22/h3-5,8-16,18,25H,1-2,6-7,17H2,(H2,31,36)(H,33,37)
SMILES Code: NC(C1=CC(CNC(C2=CC=C3C(N(C4CCCC4)C(C5=CC(C=CN=C6)=C6C=C5)=N3)=C2)=O)=CC=C1)=O
Appearance: To be determined
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info: The discovery of monokinase-selective inhibitors for patients is challenging because the 500+ kinases encoded by the human genome share highly conserved catalytic domains. Until now, no selective inhibitors unique for a single transforming growth factor β (TGFβ) family transmembrane receptor kinase, including bone morphogenetic protein receptor type 2 (BMPR2), have been reported. This dearth of receptor-specific kinase inhibitors hinders therapeutic options for skeletal defects and cancer as a result of an overactivated BMP signaling pathway.
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 489.58 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
Modukuri RK, Monsivais D, Li F, Palaniappan M, Bohren KM, Tan Z, Ku AF, Wang Y, Madasu C, Li JY, Tang S, Miklossy G, Palmer SS, Young DW, Matzuk MM. Discovery of Highly Potent and BMPR2-Selective Kinase Inhibitors Using DNA-Encoded Chemical Library Screening. J Med Chem. 2023 Jan 31. doi: 10.1021/acs.jmedchem.2c01886. Epub ahead of print. PMID: 36719862.
